The product contains the active ingredient levocetirizine, which is the enantiopure version of cetirizine, the active ingredient in UCB’s blockbuster product Zyrtec®. In February 2008 UCB and Sanofi Aventis, who are co-marketing the product, announced the FDA approval of Xyzal® Oral Solution. The Oral Solution product offers an alternative for patients who have difficulty swallowing or who prefer liquid medication.
Synthon’s recent ANDA filing forms part of a rich pipeline of research projects and pending regulatory applications. Synthon’s management is confident that the current PIV filing will bring considerable value to the company.
Synthon is a privately owned specialty pharma company. With facilities in seven different countries, the company is dedicated to research, development, production, licensing and marketing of high quality alternatives to innovative medicines.
For more information please contact PR@synthon.com, or call Synthon Pharmaceuticals, Inc.
at + 1 919 493 6006 .
For further information on Synthon Pharmaceuticals, Inc please see www.synthon-usa.com.
For further information on the Synthon group of companies, please see www.synthon.com.
Xyzal® is a trademark of UCB Pharma SA.
Zyrtec® is a trademark of UCB Pharma SA.